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ABSTRACT
OBJECTIVE: To test the hypothesis that multicenter automatic defibrillator implantation trial (MADIT) - implantable car-
dioverter-defibrillator (ICD) scores predict replacement requirement and appropriate shock in a mixed population including 
both primary and secondary prevention and long-term adverse cardiovascular events.
METHODS: The study has a retrospective design. Patients who were implanted with ICD in the cardiology clinic of Atatürk 
University Faculty of Medicine between 2000 and 2013 were included in the study. For this purpose, 1394 patients who were 
implanted with a device in our clinic were reviewed. Then, those who were implanted with permanent pacemaker (n=1005), 
cardiac resynchronization treatment (CRT) (n=45) and CRT-ICD (n=198) were excluded.
RESULTS: A total of 146 patients (98 males, 67.1%) with a mean age of 61.1 (±14.8) years were recruited. The median 
follow-up time was 21.5 months (mean 30.6±25.9 months; minimum 4 months, and maximum 120 months). The median 
MADIT-ICD scores in the patients were 2. MADIT-ICD scores were categorized as low in 15.1%, intermediate in 57.5%, and 
high score in 27.4% of patients. Accordingly, MADIT-ICD scores (1.29 [1.00–1.68], p=0.050), hemoglobin (0.86 [0.75–0.99], 
p=0.047), and left ventricular ejection fraction (EF) (0.97 [0.94–0.99], p=0.023) were determined as independent predictors 
of major adverse cardiovascular events in the long-term follow-up of ICD-implanted population.
CONCLUSION: In this study, we showed that there was an independent association of long-term adverse cardiovascular 
events with MADIT-ICD score, hemoglobin, and EF in patients implanted with ICD.
Keywords: Cardiovascular events; implantable cardioverter defibrillator; reduces mortality.
Received: November 24, 2017   Accepted: February 01, 2018   Online: August 13, 2018
Correspondence: Dr. Abdulkadir USLU. Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, 
Kardiyoloji Klinigi, Cevizli, Kartal, Istanbul, Turkey.
Tel: +90 505 421 21 06   e-mail: dr.akadiruslu@gmail.com
© Copyright 2019 by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com
North Clin Istanb 2019;6(1):40-47
doi: 10.14744/nci.2018.69335
Relation of multicenter automatic defibrillator 
implantation trial implantable cardioverter-defibrillator 
score with long-term cardiovascular events in patients 
with implantable cardioverter-defibrillator
Orıgınal Article   CARDIOLOGY
Cite this article as: Uslu A, Dogan C, Duman H, Tanboga IH, Askin L, Sevimli S. Relation of multicenter automatic defibrillator implantation 
trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator 
North Clin Istanb 2019;6(1):40-47.
Implantable cardioverter-defibrillator (ICD) treat-ment reduces mortality due to cardiovascular events 
in patients with high-risk cardiovascular disease, is-
chemic heart disease, cardiomyopathy, congestive heart 
failure, and new-onset ventricular arrhythmia [1]. ICD 
treatment results in approximately 20% reduction in to-
tal mortality rate in primary and secondary prevention, 
and approximately 50% reduction in mortality due to 
arrhythmia after myocardial infarction (MI) [2, 3]. On 
the other hand, it does not provide symptomatic relief; 
however; possible mortality due to adverse arrhythmic 
events is reduced. Therefore, to provide optimal medi-
cal care to patients with ICD and to reduce health-care 
costs, it is important that the risk factors associated with 
morbidity and mortality are identified [2]. However, we 
are still unable to identify such patients effectively.
The multicenter automatic defibrillator implantation 
trial (MADIT) II showed that primary ICD therapy im-
proves survival in patients with a prior MI and advanced 
left ventricular dysfunction. Furthermore, Goldenberg et 
al. [4] have recently developed a simple risk score for as-
sessment of ICD efficacy, and all-cause mortality in the 
MADIT-II population. This score categorizes patients 
in low, moderate, and high-risk groups based on clinical 
and laboratory parameters such as age, atrial fibrillation 
(AF), QRS duration, functional capacity, and urea levels.
MADIT-ICD score was developed in a primary pre-
vention population, and its correlation with all-cause 
mortality was investigated. Its correlation in secondary 
prevention patients, or its association with end-points 
other than all cause-mortality such as replacement re-
quirement, or with appropriate shock have not been 
studied yet. For that reason, in the present study, we in-
vestigated the association between MADIT-ICD scores 
of patients with ICD implanted for either primary or 
secondary prevention, and end-points other than all-
cause mortality such as replacement requirement, and 
with major adverse cardiovascular events (MACE) in the 
long term such as appropriate shock.
MATERIALS AND METHODS
Study population 
The study has a retrospective design. Patients who were 
implanted with ICD in the cardiology clinic of Atatürk 
University Faculty of Medicine between 2000 and 2013 
were included in the study. For this purpose, 1394 pa-
tients who were implanted with a device in our clinic 
were reviewed. Then, those who were implanted with 
permanent pacemaker (n=1005), cardiac resynchroniza-
tion treatment (CRT) (n=45) and CRT-ICD (n=198) 
were excluded. As a result, the study included 146 pa-
tients who were implanted with only ICD. MACE that 
occurred in these patients during the long-term follow-up 
were identified, and their association with MADIT-ICD 
scores was evaluated. The study was approved by the local 
ethics committee.
MADIT–ICD score
MADIT-ICD scores are calculated with consideration 
of 5 clinical parameters (blood urea nitrogen [BUN] 
>26 mg/dl, functional capacity >2, presence of AF, age 
>70, and QRS >120 m s). Each positive parameter is 
given 1 point. A total of 0 point indicates the low score, 
1–2 points indicate intermediate score, and ≥3 points in-
dicate high score [5]. 
Clinical evaluation and definitions
Patient files were reviewed with regard to clinical and 
biochemical parameters and device properties. Diabetes 
mellitus was defined as fasting blood glucose level mea-
sured at least twice as >126 mg/dL, hemoglobin A1c level 
measured as >6.5%, or use of an antidiabetic medication 
[5]. HT was defined as blood pressure measured at least 
twice as >140/90 mmHg, or use of antihypertensive med-
ication [6]. Chronic kidney disease (CKD) was defined as 
estimated glomerular filtration rate (GFR) <60 ml kg/
min. Estimated GFR was calculated based on the Cock-
croft-Gault formula. In addition, the previous history of 
percutan interventions, coronary by-pass, and cerebrovas-
cular events was noted. Heart rate, QRS duration, and 
presence of AF were determined from the electrocardio-
grams performed at the time of admission. For all patients, 
the results of complete blood count and biochemical tests 
sent at the time of admission were recorded. Left ventricu-
lar ejection fraction (EF) measured with biplane Simpson 
in echocardiography examination at the time of admission 
was recorded. ICD indications ischemic and non-ischemic 
cardiomyopathy (CMP), hypertrophic CMP, arrhythmo-
genic right ventricular dysplasia, primary electrical distur-
bances, type of prevention (primary or secondary preven-
tion), and type of ICD (VVI, DDD) were recorded.
End points 
Patient files were reviewed to identify adverse cardio-
vascular events. A combined end-point was established 
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from all-cause mortality, replacement requirement, and 
incidence of appropriate shock (MACE: Major adverse 
cardiovascular events).
Statistical analysis
Normally distributed numerical variables were expressed 
as mean±standard deviation; non-normally distributed 
variables were expressed as median (minimum-maxi-
mum); whereas categorical variables were expressed as 
a percentage. To test the distribution characteristic of 
numerical variables, the Kolmogorov–Smirnov test was 
used. To determine the differences regarding numerical 
variables between the groups, Students t-test or Mann–
Whitney U-test was used. To determine the differences 
regarding categorical variables between the groups, Chi-
square test was used. Using Kaplan–Meier survival anal-
ysis, mortality, replacement requirement, the incidence of 
appropriate shock, and MACE were analyzed according 
to the groups of MADIT-ICD scores in the whole pop-
ulation. Difference between these groups was analyzed 
with Log-rank test. Those variables that were found to 
be significant in the univariate analysis of groups with 
or without MACE development were included in Cox 
regression analysis (p<0.05). Age, BUN, and functional 
capacity were found to be significant in univariate anal-
ysis; however, since these are items of the MADIT-ICD 
scores, they were not included in the Cox regression 
analysis. In statistical analyses, p<0.05 was accepted as 
significant. All statistical analyses were performed using 
SPSS (version 20) statistical package software.
RESULTS
The study included 146 patients who were implanted 
with ICD (mean age was 61.1±14.8 years, and 67.1% of 
the patients were male). Basic clinical and biochemical 
parameters of the patient population are summarized in 
Table 1. The median MADIT-ICD scores in the patient 
population were 2. MADIT-ICD scores were catego-
rized as low in 15.1%, moderate in 57.5%, and high score 
in 27.4% of patients (Fig. 1).
The median follow-up time was 21.5 months (mean 
30.6±25.9 months; minimum 4 months, and maximum 
120 months). During the follow-up, 45.2% of the pa-
tients (n=66) developed MACE. Among these, all-cause 
mortality was detected in 21.2% (n=31), appropriate 
shock was detected in 25.3% (n=37), and replacement 
requirement was detected in 17.8% (n=26) of the pa-
Age, years (average±SD) 61.1±14.8
Sex (male, %) 67.1
Diabetes mellitus, % 16.4
Hypertension, % 49.3
Smoker, % 40.0











 Long QT 2.7
PCI history, % 15.8
CABG history, % 21.2
History of SVE, % 6.8
Left ventricle ejection fraction, % 38.6±12.6
Mitral Regurgitation, (extreme, %) 10.3
Systolic pulmonary blood pressure, (average±SD) 38.7±11.1
Atrial fibrillation, % 12.3
QRS duration, (average±SD) 99.7±22.8
Systolic blood pressure, (average±SD) 113±14
Diastolic blood pressure, (average±SD) 72±9.6
Heart rate, (average±SD) 83±11
ICD Implantation indication, %
 Primer protection 24.6
 Seconder protection 75.4
Implanted ICD type, %
 VVI-ICD 65.1
 DDD-ICD 34.9
URE, (mg/dl) (average±SD) 26.7±14.4
Creatinine, (mg/dl) (average±SD) 1.08±0.4
Sodium, (meq/l) (average±SD) 137±4.4
Potassium, (meq/l) (average±SD) 4.4±0.5
Troponin, (µg/l) (average±SD) 0.8±3.3
White blood cell, x 103 µL (average±SD) 9.7±3.1
Hemoglobin, (g/dl) (average±SD) 13.8±2.0
Platelet, x 103 µL (average±SD) 237±67
ARVD: Arrhythmogenic right ventricular dysplasia; ICD: Implantable cardio-
verter defibrillator; SD: Standard deviation.
Table 1. Basic clinical and laboratory features
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tients. Replacement indications were identified as the 
drained battery in 11 patients, pouch infection in 5 pa-
tients, infective endocarditis in 3 patients, trauma in 1 
patient, and ICD malfunction in 1 patient.
After categorizing the patient population according to 
the MADIT-ICD scores as low, moderate, and high score 
groups, MACE development in the long-term follow-up 
was analyzed again in these groups (Table 2). Results of 
both Kaplan–Meier survival analysis and the Chi-square 
test showed that the incidence of MACE increased signif-
icantly as the severity of MADIT-ICD scores increased. 
Replacement requirement also increased with increasing 
MADIT-ICD score; however, there was a limited statisti-
cal association. The incidence of appropriate shock did not 
show association with MADIT-ICD scores. As a result, 
the increase observed in MACE as MADIT-ICD scores 
increased was driven by all-cause mortality (Figs. 2-4).
There was a significant difference between the groups 
with and without MACE development in terms of age, 
hypertension, ischemic CMP, CKD, functional capacity, 
left ventricular EF, systolic pulmonary artery pressure 
(PAP), BUN, creatinine, hemoglobin, and MADIT-
ICD scores. The other examined variable did not a sig-
nificant difference between the two groups (Table 3).
To identify the independent predictors of MACE, 
Cox proportional-Hazard analysis was employed. As 
univariate analysis showed MADIT-ICD scores, sys-
tolic PAP, hemoglobin, creatinine, and left ventricular 
EF as significant, these variables were included in the 
Cox-regression analysis. Accordingly, MADIT-ICD 
scores (1.29 [1.00–1.68], p=0.050), hemoglobin (0.86 
[0.75–0.99], p=0.047), and left ventricular EF (0.97 
[0.94–0.99], p=0.023) were determined as independent 
predictors of MACE in the long-term follow-up of ICD-
implanted population (Table 4).
Figure 2. Incidences of mortality, replacement requirement, 
shock and major adverse cardiovascular events in the long-
term follow-up according to the multicenter automatic de-














































Variables (%) Low MADIT-ICD Middle MADIT-ICD High MADIT-ICD p* p** 
  score (n=22) score (n=84) score (n=40)
Death due to all causes 9.1 16.7 37.5 0.001 0.004
Replace need 4.5 17.9 25 0.716 0.051
Shock  13.6 25 32.5 0.153 0.107
Major unwanted cardiac sum of events 18.2 44 62.5 0.002 0.001
*The p-value found by the log-rank test for the MADIT-ICD score subgroups; **The p value found by the X2 test for the MADIT-ICD score subgroups.
Table 2. Adverse cardiac events according to the MADIT-ICD score groups
Figure 1. Distribution of multicenter automatic defibrillator im-
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DISCUSSION
In the present study, we found that MADIT-ICD 
scores were an independent predictor of all-cause 
mortality and MACE in the long-term follow-up of 
patients who were implanted with ICD for either pri-
mary or secondary prevention purpose. In addition, we 
showed that this scores could also be useful for pre-
dicting long-term events regarding left ventricular EF 
and hemoglobin levels.
Sudden cardiac arrest is encountered as the first 























































Figure 3. Kaplan–Meier survival curve for major adverse car-
diovascular events (left) and mortality (right) according to 
the multicenter automatic defibrillator implantation trial-im-























































Figure 4. Kaplan–Meier survival curve for replacement re-
quirement (left) and incidence of appropriate shock (right) 
according to the multicenter automatic defibrillator im-
plantation trial-implantable cardioverter-defibrillator score 
groups in the whole population.
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the hospital [7, 8]. The underlying cause is known to be 
malignant ventricular arrhythmias in 80–90% of such 
patients [9]. Nevertheless, only a minority of patients 
presenting with sudden cardiac arrest is responsive to 
resuscitation, and even in areas of best health condi-
tions, the maximum reported response rate was 3% 
[10]. In all patient populations, the major malignant 
arrhythmias causing sudden cardiac death are known 
Variables  MACEs (-) (n=80) MACEs (+) (n=66) p
Age, years (average±SD) 58.0±15.7 64.8±12.6 0.005
Sex (male, %) 67.5 66.7 0.915
Diabetes mellitus, % 12.5 21.2 0.157
Hypertention, % 42.5 57.6 0.070
Smoker, % 41.3 38.5 0.733
Choronic renal failure, % 1.3 12.1 0.007
Fonctional capacity, %
 NYHA-I 1.3 0
 NYHA-II 31.3 13.6 
0.009 NYHA-III 52.5 62.1
 NYHA-IV 15.0 24.2
Ischemic cardiomyopathy, % 58.8 72.7 0.078
Other cardiomyopathy, %
 Nonischemic 12.5 16.7
 Hypertrophic  17.5 7.6 0.048
 ARVD 6.3 0
PCI history, % 15 16.7 0.783
CABG history, % 22.5 19.7 0.680
History of SVE, % 6.3 7.6 0.752
Left ventricle ejection fraction, % 40.9±13.7 35.8±10.7 0.013
Systolic pulmonary blood pressure, (average±SD) 36.8±11.4 41.1±10.4 0.020
Atrial fibrillation, % 10.0 15.2 0.346
QRS duration, (average±SD) 98.1±22.4 101±23 0.354
Systolic blood pressure, (average±SD) 113±14 112±14 0.747
Diastolik blood pressure, (average±SD) 72±10 71±9 0.527
Heart rate, (average±SD) 82.5±10.6 83.6±11.4 0.538
ICD implantation endication, %
 Primer protection 23.8 25.8 
0.778 Sekonder protection 76.3 74.2
Implanted ICD type, %
 VVI-ICD 66.3 63.6 
0.742 DDD-ICD 33.8 36.4
URE, (mg/dl) (average±SD) 24.5±11.6 29.3±16.9 0.041
creatinine, (mg/dl) (average±SD) 1.0±0.2 1.1±0.5 0.035
Sodium, (meq/l) (average±SD) 138±3.8 137±5 0.412
Potassium, (meq/l) (average±SD) 4.4±0.5 4.3±0.5 0.795
Troponin, (µg/l) (average±SD) 1.1±4.4 0.4±1.0 0.155
White blood cell, x 103 µL (average±SD) 9.8±3.1 9.5±3.0 0.195
Hemoglobin, (g/dl) (average±SD) 14.2±1.8 13.4±2.1 0.018
Platelet, x 103 µL (average±SD) 237±63 237±72 0.989
MADIT-ICD score (median) 1.5 2 0.001
ARVD: Arrhythmogenic right ventricular dysplasia; ICD: Implantable cardioverter defibrillator; SD: Standard deviation.
Table 3. Comparison of the major clinical and laboratory findings of MACEs with and without development
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to be ventricular tachycardia attacks that degenerate 
to ventricular fibrillation [11, 12]. Furthermore, it is 
a known fact that nearly half of these patients are lost 
within 2 years unless they are properly treated. Some 
previous studies reported similar mortality rates in 
comparison to ICD implantation and medical treat-
ment and that some unwanted clinical conditions may 
develop due to the shocks; [13, 14] however, as a result 
of many clinical studies, it is currently a well-accepted 
view that ICD implantation for both primary and sec-
ondary prevention reduces mortality [15, 16].
As it is stated, it is accepted that ICD implanta-
tion reduces mortality in comparison to the medical 
treatment; however, there is controversy about patient 
selection. At present, it is not clearly known which 
patients will develop adverse events in the long-term 
following ICD implantation, or what its predictors 
are. MADIT-ICD scores are used commonly as an 
up-to-date scoring system related with this subject. It 
is known that it yields favorable results in predicting 
which patients in the primary prevention population 
will develop adverse events. MADIT-ICD scores were 
initially developed by Goldenberg et al. [4] They fol-
lowed up patients who were implanted with ICD for 
primary prevention purpose for nearly 7 years. They 
divided patients into high, intermediate, and low-risk 
groups based on 5 pre-determined clinical risk factors. 
The results of the study showed that ICD implanta-
tion was beneficial in the low and intermediate risk 
groups; however, it did not have long-term benefit in 
the high-risk group (positive for at least three clinical 
parameters). In their study, Iwona et al. [17] accepted 
all-cause mortality as an endpoint in a population sim-
ilar to that of MADIT study, and they showed that in 
addition to MADIT-ICD scores, some clinical param-
eters were also significant in predicting long-term mor-
tality in a group of patients who were implanted with 
ICD for primary prevention purpose. Recently, Nak-
suk et al. [18] stated that in a more limited population 
that was similar to that of MADIT, MADIT scores 
were useful in predicting all-cause mortality; however, 
they suggested that this scoring did not have a pre-
dictive value for appropriate shock. Similarly, we also 
found that there was no association between appro-
priate shock and MADIT-ICD scores. In the present 
study, we investigated a patient population who were 
implanted with ICD for both primary and secondary 
prevention, but mostly secondary prevention; and we 
showed that MADIT-ICD scores were useful in pre-
dicting MACE in this population, and we also found 
that hemoglobin and EF also had an independent as-
sociation with MACE as well.
For the 1st time in literature, we showed that 
MADIT-ICD scores were beneficial in predicting 
long-term mortality as well as clinical end-points such 
as replacement requirement and appropriate shock in 
a mixed population including both primary and sec-
ondary prevention. Our results indicate that a simple 
and convenient scoring system such as MADIT-ICD 
scores is beneficial in predicting adverse event devel-
opment in the long-term in a high-risk population of 
patients who underwent ICD therapy. Therefore, we 
showed that utilization of this score in patients who 
underwent ICD treatment would aid in identifying 
high-risk patients. Such patients may receive a more 
intensive treatment to achieve clinical improvement.
Study limitations
The major limitations of the present study are that it was 
conducted in a single-center and did not have a prospec-
tive design. In addition, although all patients undergo-
Variables  Univariate HR, Univariate  Multivariate HR, Multivariate 
  %95 GA p value %95 GA p value
MADIT-ICD score 1.35 (1.09–1.67) 0.001 1.29 (1.00–1.68) 0.050
PBPs 1.01 (0.99–1.03) 0.020 1.00 (0.98–1.03) 0.654
Hemoglobin 0.86 (0.75–0.99) 0.018 0.86 (0.75–0.99) 0.047
Creatinine 1.36 (0.83–2.22) 0.035 0.75 (0.41–1.37) 0.358
LV-EF 0.97 (0.94–0.99) 0.013 0.97 (0.94–0.99) 0.023
Table 4. Cox regression analysis for predicting MACE
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ing ICD implantation in our clinic were included in the 
study, our patient number was limited, which was an-
other limitation of this study. In addition, the original 
population in which MADIT-ICD scores were defined 
included only patients who underwent ICD implanta-
tion for primary prevention, and the defined end-point 
was all-cause mortality only, which present the main dif-
ferences from our study.
Conclusion
In this study, we showed that there was an independent 
association of long-term adverse cardiovascular events 
with MADIT-ICD scores, hemoglobin, and EF in pa-
tients implanted with ICD. These parameters may be 
used in risk stratification of ICD-implanted patients to 
contribute in optimal care, improvement of life quality, 
and reduction of treatment costs in such patients.
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